Note: Published earlier in 2015.

Drs. Stephen A. Harrison and Saleh A. Alqahtani discuss the paper: Safety and Tolerability of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Phase III ION Trials.

Note: Published earlier in 2015. Drs. Stephen A. Harrison and Saleh A. Alqahtani discuss the paper: Safety and Tolerability of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Phase III ION Trials.

Ledipasvir/Sofosbuvir Safety+Tolerability With&Without Ribavirin in Chronic HCV Infection

Vision
To Prevent and Cure Liver Disease

Mission
To advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care

AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists (including Hans Popper, Leon Schiff, Fred Hoffbauer, Cecil Watson, Jesse Bollman, and Sheila Sherlock, to name a few) to bring together those who had contributed to the field of hepatology. 

AASLD has grown to an international society responsible for all aspects of hepatology, and our annual meeting, The Liver Meeting®, has grown in attendance from 12 to over 9,500 physicians, surgeons, researchers, and allied health professionals from around the world.

Hepatology has been recognized as a discipline only in the last few decades, and AASLD played a seminal and unifying role in focusing interest on hepatological problems, as well as the founding of other hepatological societies. 

Our three monthly journals, HEPATOLOGY, Liver Transplantation, and Clinical Liver Disease provide the latest research findings for hepatology and surgery of the liver.

AASLD's membership includes ALL professionals dedicated to hepatobiliary discoveries and patient care. Mentoring, the sharing of knowledge, and dedication to professional growth and development are among the core values of AASLD and its members.

Science

Vision To Prevent and Cure Liver Disease Mission To advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists (including Hans Popper, Leon Schiff, Fred Hoffbauer, Cecil Watson, Jesse Bollman, and Sheila Sherlock, to name a few) to bring together those who had contributed to the field of hepatology. AASLD has grown to an international society responsible for all aspects of hepatology, and our annual meeting, The Liver Meeting®, has grown in attendance from 12 to over 9,500 physicians, surgeons, researchers, and allied health professionals from around the world. Hepatology has been recognized as a discipline only in the last few decades, and AASLD played a seminal and unifying role in focusing interest on hepatological problems, as well as the founding of other hepatological societies. Our three monthly journals, HEPATOLOGY, Liver Transplantation, and Clinical Liver Disease provide the latest research findings for hepatology and surgery of the liver. AASLD's membership includes ALL professionals dedicated to hepatobiliary discoveries and patient care. Mentoring, the sharing of knowledge, and dedication to professional growth and development are among the core values of AASLD and its members.

Share Ledipasvir/Sofosbuvir Safety+Tolerability With&Without Ribavirin in Chronic HCV Infection

Sign up to save your podcasts

Ledipasvir/Sofosbuvir Safety+Tolerability With&Without Ribavirin in Chronic HCV Infection

Ledipasvir/Sofosbuvir Safety+Tolerability With&Without Ribavirin in Chronic HCV Infection

More shows like HEPATOLOGY Podcast

American Journal of Gastroenterology Author Podcasts